---
title: "Humana Price Target Raised to $370 as Margin Recovery Prospects Balance Ongoing Execution Risks, Supporting Hold Rating"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294434426.md"
description: "TD Cowen analyst Ryan Langston raised Humana's price target to $370 from $350, maintaining a Hold rating. The upgrade reflects improved fundamentals and margin recovery prospects driven by benefit redesign and administrative efficiencies. However, the Hold rating persists due to ongoing execution risks regarding bids, enrollment, and quality metrics needed to meet long-term goals. Barclays also maintained a Hold rating with a $344 target."
datetime: "2026-07-31T00:55:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294434426.md)
  - [en](https://longbridge.com/en/news/294434426.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294434426.md)
---

# Humana Price Target Raised to $370 as Margin Recovery Prospects Balance Ongoing Execution Risks, Supporting Hold Rating

Analyst Ryan Langston from TD Cowen maintained a Hold rating on Humana and increased the price target to $370.00 from $350.00.

Ryan Langston has given his Hold rating due to a combination of factors, balancing improving fundamentals with execution risk. He acknowledges management’s confidence in a multi‑year margin recovery, supported by benefit redesign, targeted plan exits, value‑based care penetration, and administrative efficiencies, and he notes that medical cost trends and updated EPS forecasts point to a healthier earnings outlook.

At the same time, he emphasizes that achieving Humana’s 2028 margin and Stars objectives still depends heavily on successful bids, enrollment outcomes, and further improvement in quality metrics. Because more progress beyond Stars gains is likely needed to fully reach internal return targets, he raises the price target to $370 but concludes that the risk‑reward profile remains balanced, justifying a Hold rather than a more aggressive rating.

In another report released yesterday, Barclays also maintained a Hold rating on the stock with a $344.00 price target.

### Related Stocks

- [HUM.US](https://longbridge.com/en/quote/HUM.US.md)
- [BCS.US](https://longbridge.com/en/quote/BCS.US.md)
- [BARC.UK](https://longbridge.com/en/quote/BARC.UK.md)

## Related News & Research

- [US Insurer Humana Is Exiting More Medicare Advantage Plans in 2027— Here's Who Could Be Affected](https://longbridge.com/en/news/294371234.md)
- [Humana Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts](https://longbridge.com/en/news/294168198.md)
- [Humana's Strong Quarter Fails To Impress](https://longbridge.com/en/news/294238110.md)
- [Humana director John P. Smith files initial beneficial ownership statement](https://longbridge.com/en/news/294247908.md)
- [REG - Evelyn Partners Grp LondonMetric Schroder Real Estate Picton Property Inc. - Form 8.3 PICTON PROPERTY INCOME LIMITED](https://longbridge.com/en/news/294364951.md)